SecBot SecBot
8-K ·Filed May 1, 2026

KNSA

Kiniksa Pharmaceuticals International, plc
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago SEC0001730430-26-000021
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

No material impact on operations or strategy given the retained advisory role. Monitor for any further C-suite departures that could signal broader organizational instability, but this single departure is routine.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
KNSA ▲ +40.44% at T+60d
NEUTRAL call +40.44% · α vs SPY +38.58% · entry $57.62 → $80.92
Entry = T+0 close
May 1, 2026
via day close
T+1d
-1.53%
call -1.53% · α -2.32%
$56.74
settled 6mo ago
T+5d
+1.30%
call +1.30% · α -1.63%
$58.37
settled 6mo ago
T+20d
-15.95%
call -15.95% · α -21.59%
$48.43
settled 5mo ago
T+60d
+40.44%
call +40.44% · α +38.58%
$80.92
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Chief Strategy Officer Eben Tessari resigned effective May 15, 2026 to pursue another executive position in life sciences, with no disagreement with the company. He will transition to a consulting role at $450/hour (up to 20 hours/month) for one year. This is a routine C-suite departure with a smooth transition and retained advisory access, not a red-flag event.

Key Facts

  • Eben Tessari resigned as Chief Strategy Officer on April 30, 2026, effective May 15, 2026
  • Resignation was voluntary to pursue another executive position in life sciences
  • No disagreement with the company on operations, policies, or practices
  • Will become a consultant at $450/hour, up to 20 hours/month, through May 15, 2027
  • Will serve as special advisor to the Science and Research Committee
  • Consulting agreement is renewable for one additional year by mutual agreement

Financial Impact

Trivial — consulting fees capped at $9,000/month ($450/hr × 20 hrs), totaling up to $108,000 annually

operatingExpenses

Risk Factors

  • Potential loss of institutional knowledge if consulting engagement is not fully utilized
  • No named successor for CSO role — could indicate the position is being eliminated or responsibilities redistributed

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001730430-26-000021
Document: 0001730430-26-000021-index-headers.html0001730430-26-000021
Document: 0001730430-26-000021-index.html0001730430-26-000021
Document: 0001730430-26-000021.txt0001730430-26-000021
16 reports for KNSA
Performance horizon
60% Hit rate @ T+60 3 of 5 directional calls Went positive at some point 5 of 5 best @ T+60▲ +17.08%Apr 28, 2026
Filters
Rows
Reports for KNSA — sortable, filterable
TypeNow
Oct 27, 2026
today
8-K
BULLISH ★ 6/10
$76.00awaiting T+60—$89.06 (+17.19%)
Oct 27, 2026
today
Press Release
BULLISH ★ 6/10
$75.00awaiting T+60—$89.06 (+18.74%)
Oct 22, 2026
4d ago
8-K
NEUTRAL ★ 2/10
$76.73awaiting T+60—$89.06 (+16.06%)
Oct 22, 2026
4d ago
Press Release
NEUTRAL ★ 1/10
$80.79awaiting T+60—$89.06 (+10.23%)
Sep 3, 2026
7w ago
144
NEUTRAL ★ 2/10
$77.91awaiting T+60—$89.06 (+14.30%)
Jul 28, 2026
13w ago
8-K
BULLISH ★ 7/10
$79.44 $79.70▲ +0.33%▼ −4.02%$89.06 (+12.10%)
Jul 28, 2026
13w ago
Press Release
BULLISH ★ 7/10
$79.44 $79.70▲ +0.33%▼ −4.02%$89.06 (+12.10%)
May 26, 2026
21w ago
8-K
NEUTRAL ★ 3/10
$51.84 $78.47▲ +51.37%▲ +49.49%$89.06 (+71.79%)
May 1, 2026
25w ago
8-K
NEUTRAL ★ 2/10
$57.62 $80.92▲ +40.44%▲ +38.58%$89.06 (+54.56%)
Apr 28, 2026
25w ago
144
BEARISH ★ 6/10
$52.99 $62.84▼ −18.59%▼ −14.48%$89.06 (−68.06%)
Showing 10 of 16

US Market Status

Market Open — Closes in 3h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 1, 2026